Sodium-potassium-chloride cotransporter (NKCC) (NKCC)

The Sodium-potassium-chloride cotransporter (NKCC) is a family of membrane proteins that mediate the electroneutral transport of one sodium, one potassium, and two chloride ions across the plasma membrane [6, 8]. In humans, there are two primary isoforms: NKCC1 (SLC12A2), which is ubiquitously expressed and involved in cell volume regulation and fluid secretion, and NKCC2 (SLC12A1), which is specifically located in the thick ascending limb of the loop of Henle in the kidney [8, 15]. NKCC2 is the primary therapeutic target for loop diuretics, such as furosemide and bumetanide, which are used to treat hypertension and edema by inhibiting renal salt reabsorption [2, 12]. NKCC1 also plays a vital role in the nervous system by maintaining high intracellular chloride levels in developing neurons, and its dysregulation is implicated in neurological disorders like epilepsy and schizophrenia [1, 3, 7]. Genetic mutations in NKCC2 lead to Bartter syndrome type 1, a condition characterized by severe salt wasting and hypokalemia [9, 10]. Therapeutic modulation of these transporters is essential for managing fluid balance, though it carries risks such as electrolyte imbalances and ototoxicity [2, 8, 13].

Other names

NKCC1NKCC2SLC12A1SLC12A2BSC1BSC2Bumetanide-sensitive cotransporterNa-K-Cl cotransporter

Inhibition of the Na⁺-K⁺-2Cl⁻ cotransporter by binding to the chloride-binding site, thereby preventing the transport of sodium, potassium, and chloride ions [2, 8, 12].